Science Corporation Raises $400M Series D Backed by Khosla Ventures, Taking Total Funding Past $900M for Its Vision-Restoring Brain Implant

Science Corporation, a neural engineering and brain-computer interface medical device company founded in 2021, said on 17 November that it has raised a $400 million Series D. The company said the financing brings its total raised past $900 million since 2021. Science is headquartered in Alameda, California, and also keeps offices in Paris, France.

Who put in the money

In its announcement, the company named Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech as backers of the round, among others. Science did not identify a lead investor, describing the raise instead as having participation from that group.

The company did not disclose a valuation. TechCrunch, citing a person familiar with the deal, reported a figure of $3.5 billion, and MassDevice reported the same number citing a Bloomberg estimate; neither figure has been confirmed by Science. The Series D follows $230 million that MedTech Dive and MassDevice reported the company raised in March 2026. MedTech Dive also noted that Science has raised $630 million since the publication of its clinical trial paper late last year. For context on comparable deals, see our running list of recently funded startups.

What Science Corporation is building

The company’s lead product is PRIMA, described by MedTech Dive and MassDevice as a retinal implant paired with camera glasses that project near-infrared light to the implant. Science says PRIMA is the first brain-computer interface CE marked to restore form vision for patients blinded by certain types of late-stage macular degeneration, and MedTech Dive reported a European commercial launch in July 2026. According to MassDevice, PRIMA was first developed by Pixium Vision, and Science acquired the implant in 2024. MedTech Dive has reported on a single-arm clinical trial of 38 patients.

In the United States, PRIMA is not FDA approved. Science says it is pursuing FDA approval through the Humanitarian Device Exemption pathway, and MedTech Dive reported that the device holds two FDA humanitarian use device designations, covering advanced geographic atrophy and Stargardt disease. The company says it will use the new capital to accelerate PRIMA availability across Europe, prepare for a US launch, and expand research, manufacturing and operational infrastructure. Science also says a substantial further investment will go toward its biohybrid program, a neural interface that integrates engineered neurons with the brain’s own circuits. More sector context is available in our coverage of biotech companies.

What the raise means for vendors

As a general pattern, a company that has just closed a nine-figure round and stated plans to expand manufacturing, research and operational infrastructure tends to open procurement conversations across several categories at once: cleanroom and contract manufacturing capacity, quality management systems, regulatory and clinical affairs support, supply chain software, and the finance and HR tooling that comes with headcount growth. Vendors watching this segment should treat the stated use of funds as the map.

Two other dynamics usually matter here. First, a transatlantic footprint — in this case a California headquarters and a Paris office — often means parallel compliance regimes, which raises demand for suppliers that can serve both EU and US requirements without duplicate workflows. Second, when a company is pursuing a US regulatory pathway while already commercializing elsewhere, buying cycles frequently run through quality and regulatory gatekeepers rather than individual departments, so documentation, auditability and validation evidence tend to carry more weight than price alone. Vendors selling into healthcare startups generally find that timing outreach to the quarter after a raise, when budgets are being allocated rather than defended, improves response rates.

Free: top-10 + totals • Paid: full list + verified contacts

This is free coverage of a funding event. Growth and Scale unlock every newly funded company we track each week, plus verified decision-maker contacts.

Start Growth
See Scale
Download sample report

Sources: Science Corporation, 17 November 2026; TechCrunch; MedTech Dive; MassDevice; headquarters per the company. Featured image: Alameda, California, by Martin Mbuthia / Wikimedia Commons, CC BY-SA 4.0, via Wikimedia Commons.